Pablo
Pelegrin Vivancos

Our research goal is to understand how our immune system detects danger and triggers inflammation. Throughout my career, I have focused on understanding inflammasomes, pyroptosis, and the P2X7 receptor, uncovering how these molecular systems shape health and disease. My scientific journey began at the University of Murcia, where I became captivated by innate immunity during my PhD with the supervision of Prof Mulero and Meseguer. After moving to the University of Sheffield and later to the University of Manchester with Prof Surprenant, I contributed to early discoveries that helped define how inflammasomes are activated and how immune cells release IL‑1β—work that strongly marked the early development of the field. In 2009, I returned to Spain to establish my laboratory at the Biomedical Research Institute of Murcia (IMIB), where I now serve as Scientific Deputy Director and Full Professor of Immunology at the University of Murcia. My group bridges molecular immunology, clinical research, and biotechnology. Together, we have explored how inflammasomes behave in human diseases, from autoinflammatory syndromes to sepsis, and how these pathways might be targeted therapeutically. I have published more than 100 research articles and my work has been widely cited, leading to recognitions such as Highly Cited Researcher (Clarivate) and inclusion in the Stanford list of most influential scientists. Beyond academic research, I enjoy transforming scientific ideas into practical tools. This motivation led me to co‑found VIVA In Vitro Diagnostics, a spin‑off dedicated to developing rapid inflammasome‑based diagnostics, and to file patents that support future clinical applications. Above all, I am passionate about mentoring young scientists and building collaborative networks. Many colleagues who trained in my lab now lead their own research across Europe and beyond—a legacy I value as much as any publication. My long‑term goal is to continue translating fundamental immunology into meaningful advances for patients suffering from inflammatory and autoinflammatory diseases.